CORAT Therapeutics GmbH receives € 38.7 Mio. funding for the clinical development of COR-101, a drug to treat hospitalized COVID-19 patients with moderate to severe symptomsClinical processing of COR-101 is financially securedPreparation for market entry in 2023...
For the fast and efficient delivery of its innovative drug COR-101 against COVID-19, CORAT Therapeutics GmbH announces the partnership with Dermapharm Holding SE, a manufacturer of branded pharmaceuticals. With its own development, production facilities as well as...
Our laboratory tests indicate that COR-101 recognizes the particularly aggressive new „delta” variant B.1.617.2, which is rapidly replacing the “alpha” variant B.1.1.7Dr. Andreas Herrmann, CEO, CORAT Therapeutics On May 10th, the WHO classified the B.1.617.2...
CORAT secures 12,7 Mio € from Lower Saxony State, private investors, and the German Ministry of Research and Education (BMBF). NBank Capital and private investors from Braunschweig, each having participated in previous financing rounds, renewed their investments. The...
CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed...
Tübingen, Germany, 23.4.2021 – CORAT Therapeutics initiated a Phase Ib/II clinical trial evaluating the safety, tolerability, and efficacy of COR-101 in a total of 45 patients at five sites in Germany CORAT Therapeutics GmbH announced the start of a clinical...
